The active ingredient in Vyvanse is lisdexamfetamine dimesylate [1]. It is a prodrug, meaning it is converted into its active form, dextroamphetamine, in the body [1]. This conversion process is what distinguishes lisdexamfetamine from other amphetamines [1].
What is lisdexamfetamine dimesylate?
Lisdexamfetamine dimesylate is a central nervous system stimulant. It works by increasing the levels of certain neurotransmitters, like dopamine and norepinephrine, in the brain, which can help improve focus and reduce impulsivity [1].
How is lisdexamfetamine different from dextroamphetamine?
Lisdexamfetamine dimesylate is a prodrug of dextroamphetamine. This means lisdexamfetamine itself is inactive until it is metabolized in the body into dextroamphetamine, which is the pharmacologically active compound [1]. This delayed activation is a key characteristic of lisdexamfetamine.
What are the other ingredients in Vyvanse?
Beyond the active ingredient lisdexamfetamine dimesylate, Vyvanse capsules contain inactive ingredients. These include microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and synthetic red iron oxide. The capsule shells are made of gelatin, titanium dioxide, and may also contain FD&C Blue #2 and/or D&C Red #28 [1].
When does Vyvanse patent exclusivity expire?
The patent exclusivity for Vyvanse is a complex issue involving multiple patents. For instance, a key patent for the composition of matter expired in August 2023 [2]. However, other patents related to methods of use or formulations might still be in effect [2]. DrugPatentWatch.com tracks these patent expirations, which are critical for the potential entry of generic versions [2].
Can generic versions of Vyvanse be made?
The expiration of key patents opens the door for generic manufacturers to develop and seek approval for their own versions of Vyvanse. These generic versions would contain the same active ingredient, lisdexamfetamine dimesylate, and are expected to be bioequivalent to the brand-name drug [2].
Who is developing generic Vyvanse?
Several pharmaceutical companies are involved in the development and potential market launch of generic lisdexamfetamine dimesylate. For example, Viatris has announced its intent to launch a generic version following patent expirations [3].
What is the history of Vyvanse patents?
Vyvanse was initially protected by several patents. The most significant was the composition of matter patent, which has now expired [2]. Additional patents might cover specific manufacturing processes or therapeutic uses, and their expiration dates vary [2].
Sources:
[1] https://www.vyvanse.com/
[2] https://drugpatentwatch.com/
[3] https://www.viatris.com/